Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen R&D Ireland
This is a 3-year follow-up study in patients who completed the last post-therapy follow-up visit of the previous Phase IIb \[NCT00882908, NCT00980330\] or Phase III \[NCT01289782, NCT01290679, NCT01281839\] study in which they received TMC435, in combination with pegylated interferon and ribavirin, for the treatment of hepatitis C infection. The entire study duration for each patients will be approximately 36 months. The medical follow-up of the patients will be performed according to the local standard of care. This study will evaluate the levels of hepatitis C virus in the blood circulation, as well as safety and alpha-fetoprotein testing and the change in sequence of HCV NS3/4A region over time in patients with confirmed detectable HCV RNA at last post-therapy follow-up visit of the previous TMC435 study. In this study the development of liver disease progression will also be assessed. No medication will be administered in this study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have previously participated in a Phase IIb or Phase III study
Must have received at least one dose of TMC435 in that study
Has completed the last post-therapy follow-up visit of the previous (LPVPS) study
You may not be if
Must be currently enrolled or plan to enroll in another study with an investigational drug or invasive investigational medical device
Have received antiviral or immunomodulating treatment, including therapeutic vaccines, for hepatitis C virus (HCV) between LPVPS and the screening visit of present study